ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST

prnewswire.com/news-release...

BERWYN, Pa., April 19, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that patient recruitment for the Company's Phase 2/3 study of buntanetap for the treatment of moderate Alzheimer's disease (AD) remains consistent with its planned development program.

To date, a total of 27 sites have now been activated and 38 patients have been screened in the Phase 2/3 study. In addition, 13 patients have been randomized to receive either one of three doses of buntanetap or placebo.

Annovis will hold an R&D webcast on Thursday, April 20, 2023 at 4 PM to review its late-stage clinical programs in AD and Parkinson's disease (PD). Details on the webcast are provide below:

Webcast details:

Date: April 20, 2023, 4PM

Participant Toll-Free Dial-In Number: 1 [phone]

Participant Toll Dial-In Number: 1 [phone]

Conference ID: 7935665

Webcast Link: events.q4inc.com/attendee/8...

[gaga1958]

I go next week 4/25 to UVA to begin this study

[NextStage in reply to gaga1958]

Are you doing the Alzheimer's study, or Buntanetap for Parkinsons? Have you already done the screening and will be going for your baseline next week?

[gaga1958 in reply to NextStage]

yes I've done the screening and next week will be the first study appt. yes, for PD.